Knee Osteoarthritis Market is segmented By Knee Osteoarthritis Treatment (Pharmacological Management, Non-Pharmacological Management, Surgery), By Dis....
Market Size in USD
CAGR12.5%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 12.5% |
Market Concentration | High |
Major Players | Anika Therapeutics, Bioventus, Sanofi/Genzyme, Taiwan Liposome Company (TLC599), Centrexion Therapeutics (CNTX-4975) |
The knee osteoarthritis market is estimated to be valued at USD 11.7 Bn in 2024 and is expected to reach USD 30.01 Bn by 2031, growing at a compound annual growth rate (CAGR) of 12.5% from 2024 to 2031. The aging population prone to knee issues along with growing obesity rates globally is expected to drive the demand for knee osteoarthritis treatments over the forecast period.
The knee osteoarthritis market is expected to grow significantly due to the rising geriatric population worldwide and the associated increase in the prevalence of osteoarthritis. Moreover, the development and approval of novel drug classes for osteoarthritis treatment such as Intra-articular tranexamic acid are expected to provide opportunities for market growth between 2024-2031.